Hesheng Technology
合生科技
Hesheng Technology (合生科技) is a synthetic biology company in FreeS Fund's biomanufacturing portfolio. FreeS first invested at the Pre-A round and continued to back it through its Series A in early 2023 . The company is led by founder and chief scientist Liu Tiangang, a distinguished professor at Shanghai Jiao Tong University's School of Life Sciences and Biotechnology, who frames microbial engineering as a "stage" that unlocks new value from matter . FreeS groups Hesheng alongside LanzaTech (蓝晶微生物), Yanwei Technology (衍微科技), and Xinsu Technology (芯宿科技) as part of its bet on AI-driven scientific discovery (AI4S) extending into biomanufacturing .
AI-generated — may contain errors, please verify.
Coverage
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
峰瑞资本·Biomanufacturing: Who Can Move Faster on the New Research Paradigm?
A Conversation with Professor Liu Tiangang on Future Industries: Biomanufacturing
峰瑞资本·Setting Off in Spring: 7 Early-Stage Companies Raise Over 800 Million | FreeS Family Funding News · Vol 14
Looking forward to working with more outstanding founders.
峰瑞资本·How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
峰瑞资本·The U.S.-China Biotech Race: Where Are the Opportunities in Synthetic Biology? | FreeS Fund Dialogue
Over the next five to ten years, which technologies will have a significant impact on synthetic biology?
峰瑞资本·
